Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis
{{output}}
Background: The use of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) in treating hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) have been shown... ...
